{
    "clinical_study": {
        "@rank": "100939", 
        "acronym": "AIRFLOW-1", 
        "arm_group": [
            {
                "arm_group_label": "Targeted Lung Denervation", 
                "arm_group_type": "Active Comparator", 
                "description": "active targeted lung denervation"
            }, 
            {
                "arm_group_label": "Sham-Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "non-active targeted lung denervation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety of Targeted Lung Denervation (or TLD) in\n      patients suffering from moderate to severe COPD.  It is hypothesized that TLD will have a\n      similar safety profile and improved physiological and functional outcomes to a sham-control."
        }, 
        "brief_title": "Targeted Lung Denervation for Patients With Moderate to Severe COPD", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "A prospective, sequential two phase multicenter, randomized double-blind, safety, &\n      feasibility study, with unblinding in Phase B at 6 months.  The goal of Phase A will be to\n      compare two energy doses and select the optimal energy dose to be utilized in Phase B.  The\n      goal of Phase B is to compare the optimal energy dose to a sham control.  All subjects will\n      be followed for a minimum of 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of COPD with FEV1 30% to 60% and FEV1/FVC <70% (post-bronchodilator);\n\n          -  Positive relative change in FEV1 and/or FVC of >12% and 200mL following\n             administration of ipratropium bromide during reversibility testing;\n\n          -  Patient \u226540 years of age at the time of consent;\n\n          -  The patient has no child bearing potential or a negative pregnancy test (serum or\n             urine), if applicable;\n\n          -  Smoking history of at least 10 pack years;\n\n          -  Non-smoking for a minimum of 4 months prior to consent and agrees to continue not\n             smoking for the duration of the study;\n\n          -  Participated in a  pulmonary rehabilitation program or engaged in regular physical\n             activity under professional supervision in the past 12 months;\n\n        Exclusion Criteria:\n\n          -  Has been less than 8 weeks following the resolution of a COPD exacerbation or active\n             respiratory infection (ex. common cold, pneumonia, etc.);\n\n          -  E.2 History of recurrent respiratory infections and/or COPD exacerbations (more than\n             2 hospitalizations within 1 year of enrollment);\n\n          -  Prior lung transplant, LVRS, BLVR, median sternotomy, bullectomy, segmentectomy,\n             pleurodesis, pleurotomy or lobectomy;\n\n          -  Documented history of other respiratory diseases (cystic fibrosis, tuberculosis,\n             vocal cord dysfunction, Churg-Strauss syndrome, allergic bronchopulmonary\n             aspergillosis);\n\n          -  Pulmonary nodule requiring follow-up or intervention unless proven benign;\n\n          -  Daily use of >10 mg of prednisone or its equivalent at the time of enrollment;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02058459", 
            "org_study_id": "AIRFLOW-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Targeted Lung Denervation", 
                "intervention_name": "Holaira\u2122 Lung Denervation System with energy delivery", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Sham-Control", 
                "intervention_name": "Holaira\u2122 Lung Denervation System without energy delivery", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Chronic obstructive pulmonary disease, targeted lung denervation, intervention, device, safety, lung function, Holaira", 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "email": "k.klooster@umcg.nl", 
                "last_name": "Karin Klooster, PhD", 
                "phone": "+31-50 3613279"
            }, 
            "facility": {
                "address": {
                    "city": "Groningen", 
                    "country": "Netherlands", 
                    "state": "The Netherlands", 
                    "zip": "9700"
                }, 
                "name": "Universtity Medical Center Groningen"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira\u2122 Lung Denervation System in Patients With Moderate to Severe COPD.", 
        "overall_contact": {
            "email": "research@holaira.com", 
            "last_name": "Gwen Gimmestad", 
            "phone": "+1 763-450-2806"
        }, 
        "overall_official": [
            {
                "affiliation": "University Medical Centre Groningen", 
                "last_name": "Dirk-Jan Slebos, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Otto-Wagner-Spital", 
                "last_name": "Arschang Valipour, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Agency for Health and Food Safety", 
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "France: Direction G\u00e9n\u00e9rale de la Sant\u00e9", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Netherlands: Medical Ethics Review Committee (METC)", 
                "United Kingdom: National Institute for Health Research"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Respiratory adverse events is defined as: worsening bronchitis, worsening dyspnea, common cold, COPD exacerbation, influenza, pneumonia, respiratory infection, respiratory failure, tachypnea and wheezing.  Subjects may have reported more than one type of respiratory adverse event.", 
            "measure": "Therapeutic interventions and rate of respiratory adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02058459"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The assessment of safety will be based on reporting of adverse events, particularly those adverse events that are respiratory in origin.", 
                "measure": "Adverse events over 3 years", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Device success is defined as ability to deliver the test device to its intended locations, provide complete circumferential treatment and removal of the test device without the report of an adverse event during the procedure.", 
                "measure": "Device Success", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measures include: FEV1, FVC, FEV1/FVC", 
                "measure": "Spirometry measures", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Change in Functional testing: Cycle Ergometry & 6MWT", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Heath-related Quality of Life (SGRQ-C & EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "description": "Procedure Success is defined as device success without the report of an adverse event through hospital discharge.", 
                "measure": "Procedure Success", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Measures include Raw, TLC, IC, ITGW", 
                "measure": "Plethysmography measures", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Holaira", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Holaira", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}